Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer (PROMISE Study)

Trial Status: active

This study evaluates how women with mutations in BRCA1/2 genes may incorporate novel sources of ovarian cancer risk information into their decisions about cancer screening and risk reducing surgery. These novel sources of ovarian cancer risk information include polygenic risk scores (PRS), and multicancer early detection tests. A polygenic risk score is a summation of genetic modifiers, which each on its own has a tiny effect on cancer risk. However, as there are many genetic modifiers, all together they may impact BRCA1/2 associated risks.